Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.42 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14865487 | 0.97 | ACE (0.41) | ACEMMECNR2 | |
| SCHEMBL8280285 | 0.95 | ACE (0.43) | ACEMME | |
| SCHEMBL8280295 | 0.95 | ACE (0.43) | ACEMME | |
| SCHEMBL8280287 | 0.90 | ACE (0.38) | ACEMME | |
| SCHEMBL8358947 | 0.88 | ACE (0.53) | ACEMME | |
| SCHEMBL8280288 | 0.88 | ACE (0.36) | ACEMME | |
| SCHEMBL13815133 | 0.80 | ACE (0.46) | ACEMME | |
| SCHEMBL8278667 | 0.80 | ACE (0.33) | ACEMME | |
| SCHEMBL13815134 | 0.78 | ACE (0.47) | ACEMME | |
| SCHEMBL8279386 | 0.75 | MME (0.30) | ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9061069-B2 | Use of constrained peptide mimic oligomers as vectorization agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-06-23 | — | — | US | disclosed |
| US-20140031277-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031277-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-30 | — | — | US | disclosed |
| US-8536136-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536136-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-17 | — | — | US | disclosed |
| US-20130012430-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | US | disclosed |
| US-8314141-B2 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2468744-A2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8039623-B2 | Peptidomimetics compound; viricides; interference in life cycle og hepatitis c virus | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039623-B2 | Peptidomimetics compound; viricides; interference in life cycle og hepatitis c virus | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090143312-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7388017-B2 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070292933-A1 | Inhibitors of serine proteases, particular HCV NS3-NS4A protease | PITLIK JANOS | 2007-12-20 | — | — | US | disclosed |
| US-7273885-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070161789-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-12 | — | — | US | disclosed |
| US-20070161789-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-12 | — | — | US | disclosed |
| US-7208600-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208600-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-24 | — | — | US | disclosed |
| WO-2005077969-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005037860-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCOPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292933-A1 | Inhibitors of serine proteases, particular HCV NS3-NS4A protease | SERPINB1, PRSS1, SPINT2 | ACE 45/4885MME 35/4885CNR2 3915/4885 |
| US-20140031277-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | ACE 20/4885MME 31/4885CNR2 4429/4885 |
| US-20090143312-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | HPN, PRSS1, PRSS3 | ACE 65/4885MME 31/4885CNR2 4602/4885 |
| US-20070161789-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | PRSS1, SERPINB1, SPINT2 | ACE 20/4885MME 31/4885CNR2 4429/4885 |
| US-20130012430-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | HPN, PRSS1, PRSS3 | ACE 65/4885MME 31/4885CNR2 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.